iRhythm Holdings (IRTC) concentration risks

The company's disclosed concentration profile combines a high-share product dependency and a small but notable reimbursement-channel exposure. Reimbursement for iRhythm Services is expected to account for substantially all revenue for the foreseeable future, a high-share product concentration with a mixed character. The structural component reflects the company's single-product business model centered on its ambulatory cardiac monitoring service; the idiosyncratic component reflects the vulnerability to any changes in reimbursement policy, coding decisions, or coverage determinations that specifically affect that service line. A negative reimbursement change would flow through the entire revenue base with no diversifying offset. Within the revenue stream, the company received approximately 24% of total revenue from the Medicare program through CMS, a low-share reimbursement-channel dependency. While the Medicare share is limited in proportion, this payer relationship carries a dependency character: Medicare reimbursement rates and coverage policies are set administratively and can be revised, and a rate reduction or coverage contraction under Medicare would affect a defined and directly traceable slice of revenue. The two disclosures are related — both describe the same service's exposure to different payer segments — but they operate at different scales. The product concentration is the dominant risk in the profile; the Medicare dependency is a more contained but policy-sensitive sub-component within it. The primary variables to monitor are reimbursement policy developments at CMS and the broader private payer landscape for ambulatory cardiac monitoring.

For the engine’s reasoning on IRTC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.